Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.47 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 5/20 | 0.46 |
| ▸ | GLA | P06280 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | EGLN2 | Q96KS0 | 7/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL30293374 | 0.98 | ALDH1A1 (0.47) | ALDH1A1KDM4ERCE1GAAGLA | |
| Hydrochloric Acid SCHEMBL31049672 | 0.98 | ALDH1A1 (0.47) | ALDH1A1KDM4ERCE1GAAGLA | |
| SCHEMBL10406955 | 0.76 | ALDH1A1 (0.50) | ALDH1A1KDM4ERCE1GAAGLA | |
| SCHEMBL1332491 | 0.74 | ALDH1A1 (0.49) | ALDH1A1KDM4ERCE1GAAGLA | |
| SCHEMBL21686239 | 0.74 | ALDH1A1 (0.49) | ALDH1A1KDM4ERCE1GAAGLA | |
| SCHEMBL17425765 | 0.74 | ALDH1A1 (0.49) | ALDH1A1KDM4ERCE1GAAGLA | |
| SCHEMBL7899954 | 0.74 | ALDH1A1 (0.52) | ALDH1A1KDM4ERCE1GAAGLA | |
| SCHEMBL1333523 | 0.74 | ALDH1A1 (0.49) | ALDH1A1KDM4ERCE1GAAGLA | |
| SCHEMBL8411017 | 0.74 | ALDH1A1 (0.49) | ALDH1A1KDM4ERCE1GAAGLA | |
| SCHEMBL5090716 | 0.74 | ALDH1A1 (0.47) | ALDH1A1KDM4ERCE1GAAGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115380027-A | Novel antimalarial agents | 肯塔基大学研究基金会 | 2022-11-22 | — | — | CN | claimed |
| CN-114846004-A | Novel antimalarial drug | 德克萨斯大学系统董事会 | 2022-08-02 | — | — | CN | claimed |
| US-20180169072-A1 | SUBSTITUTED TRIAZOLO BICYCLIC COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME LLC | 2018-06-21 | — | — | US | claimed |
| EP-3328840-A1 | SUBSTITUTED TRIAZOLO BICYCLIC COMPOUNDS AS PDE2 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2018-06-06 | — | — | EP | claimed |
| WO-2017003894-A1 | SUBSTITUTED TRIAZOLO BICYCLIC COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-01-05 | — | — | WO | claimed |
| EP-1633756-A2 | A2A ADENOSINE RECEPTOR ANTAGONISTS | Biogen Idec MA Inc. (US) | 2006-03-15 | — | — | EP | claimed |
| WO-2004092173-A2 | A2A ADENOSINE RECEPTOR ANTAGONISTS | BIOGEN IDEC MA INC. (US) | 2004-10-28 | — | — | WO | claimed |
| WO-2026107227-A1 | COMPOSITIONS COMPRISING USP1 INHIBITORS AND METHODS OF USING THE SAME | EIKON THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| CN-121662757-B | Raw polar plate colloid battery and preparation process thereof | 武汉长光电源有限公司 | 2026-05-15 | — | — | CN | disclosed |
| WO-2026089632-A1 | 7-АМINO-[1,2,4]TRIAZOLO[1,5-А]PYRIMIDINE DERIVATIVES AND PHARMACEUTICALLY ACCEPTBALE SALTS THEREOF HAVING ANTIVIRAL AND ANTIMICROBIAL ACTIVITY | Общество с ограниченной ответственностью "Фармавирон" | 2026-04-30 | — | — | WO | disclosed |
| WO-2026089632-A1 | 7-АМINO-[1,2,4]TRIAZOLO[1,5-А]PYRIMIDINE DERIVATIVES AND PHARMACEUTICALLY ACCEPTBALE SALTS THEREOF HAVING ANTIVIRAL AND ANTIMICROBIAL ACTIVITY | Общество с ограниченной ответственностью "Фармавирон" | 2026-04-30 | — | — | WO | disclosed |
| WO-2025233865-A1 | ENPP1 INHIBITORS | RE VENTURES I, LLC (US) | 2025-11-13 | — | — | WO | disclosed |
| CN-116621840-B | 6-Nitro-7-amino- [1,2,4] triazole [1,5-a ] pyrimidine, synthesis method and application | 西安近代化学研究所 | 2025-05-13 | — | — | CN | disclosed |
| EP-1828190-A1 | 7-AMINO-6-HETEROARYL-1,2,4-TRIAZOLOÝ1,5-A¨PYRIMIDINES AND TO THE USE THEREOF FOR COMBATING PATHOGENIC FUNGI | BASF AKTIENGESELLSCHAFT (DE) | 2007-09-05 | — | — | EP | disclosed |
| US-20070173505-A1 | A2a adenosine receptor antagonists | BIOGEN IDEC MA INC. | 2007-07-26 | — | — | US | disclosed |
| WO-2007023018-A1 | 7-AMINO-6-TRIAZOLYL-1,2,4-TRIAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AND THE USE THEREOF FOR CONTROLLING HARMFUL FUNGI | BASF AKTIENGESELLSCHAFT (DE) | 2007-03-01 | — | — | WO | disclosed |
| WO-2006108792-A1 | NEW HETEROCYCLYLETHYLBENZAMIDE DERIVATIVES | BAYER CROPSCIENCE SA (FR) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006079480-A1 | PESTICIDAL SUBSTITUTED THIOETHERS | MERIAL LTD. (US) | 2006-08-03 | — | — | WO | disclosed |
| WO-2006066799-A1 | 7-AMINO-6-HETEROARYL-1,2,4-TRIAZOLO[1,5-A]PYRIMIDINES AND TO THE USE THEREOF FOR COMBATING PATHOGENIC FUNGI | BASF AKTIENGESELLSCHAFT (DE) | 2006-06-29 | — | — | WO | disclosed |
| EP-1149835-A1 | FAT ACCUMULATION INHIBITORY AGENTS | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2001-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173505-A1 | A2a adenosine receptor antagonists | ADORA2A, ADORA1, ADORA3 | ALDH1A1 357/4885KDM4E 2402/4885RCE1 2020/4885 |
| US-20180169072-A1 | SUBSTITUTED TRIAZOLO BICYCLIC COMPOUNDS AS PDE2 INHIBITORS | PDE2A, PDE3A, PDE4D | ALDH1A1 1376/4885KDM4E 2962/4885RCE1 937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.